Chagas disease (CD), caused by the protozoan Trypanosoma cruzi, remains an important public health issue in many Central and South American countries, as well as non-endemic areas with high rates of immigration from these countries. Existing treatment options for CD are limited and often unsatisfactory. Moreover the lack of post-treatment tests of cure limits the development of new drugs. To address this issue, we sought to identify serum biomarkers following nifurtimox (Nfx) treatment that could be used as an early test of cure and/or markers of a therapeutic response.
Santamaria, C.; Chatelain, E.; Jackson, Y.; Miao QuanQian; Ward, B.J.; Chappuis, F.; Ndao, M. Serum biomarkers predictive of cure in Chagas disease patients after nifurtimox treatment. BMC Infectious Diseases (2014) 14 (1) 302. [DOI: 10.1186/1471-2334-14-302]
Serum biomarkers predictive of cure in Chagas disease patients after nifurtimox treatment